Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Adaptive Biotechnologies Corp

ADPT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$24.74

▲ +1.14%

Market Cap $3.95B · Vol 604.68K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.95B

Mid Cap

Div Yield

N/A

EPS Growth

-39.74%

YoY

RSI (14)

61.65

Momentum

Beta

2.09

vs Market

52W High

$26.15

5.39% below

52W Low

$11.93

107.38% above

Volume

604.68K

Avg 924.01K

P/B

11.41

Price-to-book

ROE

-28.23%

Return on equity

Free Float

98.38%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Adaptive Biotechnologies Corp (ADPT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADPT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.76%

+15.45%

+87.71%

+54.24%

YTD

+52.34%

+91.49%

+293.32%

-22.20%

Financials & Valuation

TTM · Annual

Total Revenue	$276.98M
Net Income	$-59,457,000.00
Revenue Growth (YoY)	+21.53%
Gross Margin	73.62%
Operating Margin	-20.62%
Net Profit Margin	-21.47%
ROE	-28.23%
ROA · ROIC	-11.30% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	8.90
P/B	11.41
P/FCF	N/A
EPS Growth	-39.74%
Outstanding Shares	159.60M

Technical Indicators

50-Day SMA	$21.20
200-Day SMA	$16.97
RSI (14)	61.65
Beta	2.09
52-Week High	$26.15
52-Week Low	$11.93

Volume Today	604.68K
Avg Daily Volume (30D)	924.01K
Relative Volume	0.65x
Volatility (10D)	49.26
Volatility (30D)	58.29
Free Float	98.38%

Analyst Consensus

BUY

Current Price $24.74

Mean Target $24.75

52W Low$11.93 52W High$26.15

Current

Target

$11.93 $26.15

Current Analyst target

+0.04% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0GG18

ISINUS00650F1093

CountryUnited States of America

Sub-IndustryBio Diagnostics & Testing

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

VCYT Veracyte Inc -3.17% IOVA Iovance Biotherapeutics Inc +7.06% 300676.SZ BGI Genomics Co Ltd -3.10% CDNA CareDx Inc -4.35% MRVI Maravai LifeSciences Holdings Inc -1.38%

Company Profile

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.